NCT02231658 is a Phase 1 clinical trial of Liraglutide in Diabetes Mellitus, sponsored by Profil Institut für Stoffwechselforschung GmbH.

Who is sponsoring NCT02231658?

NCT02231658 is sponsored by Profil Institut für Stoffwechselforschung GmbH.

What drugs are being tested in NCT02231658?

Interventions in NCT02231658: Liraglutide, Lixisenatide.

What condition does NCT02231658 study?

NCT02231658 studies Diabetes Mellitus.

Is NCT02231658 still recruiting?

NCT02231658 is currently terminated. Last updated 17 October 2018.

Last reviewed 2018-10-17 · How we verify

NCT02231658

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Terminated Phase 1 Last updated 17 October 2018

What this trial tests

Phase 1 trial testing Liraglutide in Diabetes Mellitus in 109 participants. Terminated before completion.

Timeline

16 July 2015

Primary endpoint
23 July 2018

23 July 2018

Quick facts

Lead sponsor	Profil Institut für Stoffwechselforschung GmbH
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	109
Start date	16 July 2015
Primary completion	23 July 2018
Estimated completion	23 July 2018
Sites	2 locations across Germany

Drugs / interventions tested

Liraglutide (liraglutide) — full drug profile →
Lixisenatide (LIXISENATIDE) — full drug profile →

Conditions studied

Diabetes Mellitus — all drugs for Diabetes Mellitus →

Sponsor

Profil Institut für Stoffwechselforschung GmbH — full company profile →

Who can join

Adults 18 to 65, any sex, with Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study will compare lixisenatide and liraglutide in a population of subjects with T2DM not optimally controlled on OADs and / or insulin, which is the target population for these medications.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

56<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes : 21-25 September 2020.
· 2020 · cited 9× · PMID 32840677 · DOI 10.1007/s00125-020-05221-5

Verify or expand the search:

Other trials of Liraglutide

Trials testing the same drug.

NCT07225816 — Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in · Phase 1 · recruiting
NCT06818292 — Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists · NA · completed
NCT06283641 — Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan. · completed
NCT06501326 — Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease · Phase 4 · unknown
NCT05756764 — Anti-obesity Pharmacotherapy and Inflammation · active not recruiting

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07392437 — Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and I · NA · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
NCT07425275 — Integrated Oral Care Intervention for Xerostomia in Diabetes Patients · NA · recruiting
NCT06918977 — Improving Glycemic Control With Telemedicine and Smart Insulin Pens · NA · recruiting

Other Profil Institut für Stoffwechselforschung GmbH trials

Trials by the same sponsor.

NCT03359590 — Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients · Phase 2 · completed
NCT03254849 — Empagliflozin and Sympathetic Nerve Traffic · Phase 4 · completed
NCT02057497 — An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms · withdrawn
NCT02518581 — Validation of the Doubly Labelled Water Method in Subjects With Type 2 Diabetes Mellitus · NA · completed
NCT01910051 — Explorative Assessment of Biomarkers in Overweight and Obese Subjects · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02231658 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Profil Institut für Stoffwechselforschung GmbH
Last refreshed: 17 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02231658.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing